EP
ELDN icon

Essential Partners’s Eledon Pharmaceuticals ELDN Stock Holding History

Essential Partners’s Portfolio ELDN Stock Details ELDN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$4.09K Sell
1,039
-3,073
-75% -$11.2K ﹤0.01% 1631
2026
Q1 		$12.7K Buy
4,112
+3,781
+1,142% +$8.9K ﹤0.01% 1134
2025
Q4 		$500 Buy
+331
New +$787 ﹤0.01% 2231

Other funds holding ELDN

BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
DCM
Defilade Capital Management Emeryville, California $747M AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
Ensign Peak Advisors
Ensign Peak Advisors Salt Lake City, Utah $60.8B AUM 42.06% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
CCM
Catalio Capital Management New York $532M AUM 171.17% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
ZP
Zimmer Partners New York $4.34B AUM 22.78% 1-Year Est. Return

Essential Partners's ELDN Position: Q2 2026 in Review

Essential Partners reduced its Eledon Pharmaceuticals (ELDN) stake by 75% in Q2 2026, selling an estimated $11.2K and leaving 1,039 shares worth $4.09K. The position accounts for ﹤0.01% of the portfolio, ranked #1631.

Essential Partners first reported a position in ELDN in Q4 2025 and has held it in 3 quarters since. The position peaked at $12.7K in Q1 2026. 161 funds tracked by Wall St. Rank hold ELDN as of Q2 2026.

  • Essential Partners held 1,039 shares of Eledon Pharmaceuticals worth $4.09K as of Q2 2026.
  • Essential Partners sold 3,073 Eledon Pharmaceuticals shares in Q2 2026, an estimated $11.2K.
  • Eledon Pharmaceuticals made up ﹤0.01% of Essential Partners's portfolio in Q2 2026, its #1631 holding.
  • Essential Partners first reported a position in Eledon Pharmaceuticals in Q4 2025 and has held it in 3 quarters since.
  • Essential Partners's Eledon Pharmaceuticals position peaked at $12.7K in Q1 2026.
  • 161 funds tracked by Wall St. Rank held Eledon Pharmaceuticals as of Q2 2026.

Based on Essential Partners's 13F filing for Q2 2026, filed 10 Aug 2026.